JP2013540734A5 - - Google Patents

Download PDF

Info

Publication number
JP2013540734A5
JP2013540734A5 JP2013528366A JP2013528366A JP2013540734A5 JP 2013540734 A5 JP2013540734 A5 JP 2013540734A5 JP 2013528366 A JP2013528366 A JP 2013528366A JP 2013528366 A JP2013528366 A JP 2013528366A JP 2013540734 A5 JP2013540734 A5 JP 2013540734A5
Authority
JP
Japan
Prior art keywords
mll
romidepsin
pharmaceutical composition
composition
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013528366A
Other languages
English (en)
Japanese (ja)
Other versions
JP5948332B2 (ja
JP2013540734A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/051173 external-priority patent/WO2012037008A2/en
Publication of JP2013540734A publication Critical patent/JP2013540734A/ja
Publication of JP2013540734A5 publication Critical patent/JP2013540734A5/ja
Application granted granted Critical
Publication of JP5948332B2 publication Critical patent/JP5948332B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013528366A 2010-09-13 2011-09-12 Mll再構成白血病の治療法 Active JP5948332B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38245910P 2010-09-13 2010-09-13
US61/382,459 2010-09-13
PCT/US2011/051173 WO2012037008A2 (en) 2010-09-13 2011-09-12 Therapy for mll-rearranged leukemia

Publications (3)

Publication Number Publication Date
JP2013540734A JP2013540734A (ja) 2013-11-07
JP2013540734A5 true JP2013540734A5 (enExample) 2015-01-08
JP5948332B2 JP5948332B2 (ja) 2016-07-06

Family

ID=44653606

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013528366A Active JP5948332B2 (ja) 2010-09-13 2011-09-12 Mll再構成白血病の治療法

Country Status (4)

Country Link
US (1) US8859502B2 (enExample)
EP (1) EP2616054A2 (enExample)
JP (1) JP5948332B2 (enExample)
WO (1) WO2012037008A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0720734A2 (pt) * 2006-12-29 2014-01-07 Gloucester Pharmaceuticals Inc Preparação da romidepsina
BR112015028997A2 (pt) * 2013-05-24 2017-10-24 4Sc Ag biomarcadores de expressão gênica e seu uso para a aplicação diagnóstica e prognóstica em pacientes potencialmente com necessidade de tratamento de inibidor de hdac
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
GB2530470A (en) * 2014-04-17 2016-03-30 Imp Innovations Ltd Methods
JP6952602B2 (ja) * 2014-07-07 2021-10-20 アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. ヒストンデアセチラーゼ阻害剤による白血病の治療
WO2021182897A1 (ko) * 2020-03-11 2021-09-16 사회복지법인 삼성생명공익재단 포스포디에스터레이즈 5 억제제를 포함하는, nk-t 세포 림프종 또는 nk 세포 백혈병 예방 또는 치료용 약학적 조성물

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2927352A1 (de) 1979-07-06 1981-02-05 Thomae Gmbh Dr K In 6-stellung substituierte benzothiazol-2(3h)-one enthaltende arzneimittel
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
GB8817743D0 (en) 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
JPH064872A (ja) 1992-06-19 1994-01-14 Sony Corp 光ディスク再生装置
JPH0764872A (ja) 1993-08-26 1995-03-10 Fujitsu Ten Ltd データ記憶制御装置
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US5776905A (en) 1996-08-08 1998-07-07 The Board Of Trustees Of The Leland Stamford Junior University Apoptotic regression of intimal vascular lesions
US6030961A (en) 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
KR20010023449A (ko) 1997-09-02 2001-03-26 나가시마 카쭈시게, 노미야마 아키히코 신규한 환상 테트라펩티드 유도체 및 그 의약 용도
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
JPH11335375A (ja) 1998-05-20 1999-12-07 Mitsui Chem Inc ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体
US6214986B1 (en) 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression
US20070148228A1 (en) 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US6511990B1 (en) 1999-09-08 2003-01-28 Sloan-Kettering Institute For Cancer Research Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
ES2347284T3 (es) 1999-12-08 2010-10-27 Cyclacel Pharmaceuticals, Inc. Uso de depsipeptido y congeneres del mismo como inmunosupresores en la prevencion o tratamiento del rechazo que sigue a un transplante y para inducir la apoptosis de celulas t cd4 o cd8 activadas.
US6828302B1 (en) 1999-12-08 2004-12-07 Xcyte Therapies, Inc. Therapeutic uses of depsipeptides and congeners thereof
CA2317003A1 (en) 2000-02-28 2001-08-28 Hidenori Nakajima Gene expression potentiator
JP2001348340A (ja) 2000-06-07 2001-12-18 Yamanouchi Pharmaceut Co Ltd ヒストン脱アセチル化酵素阻害剤
ES2321584T3 (es) 2000-07-17 2009-06-09 Astellas Pharma Inc. Fk228 reducido y su uso.
AU2001285042A1 (en) 2000-08-18 2002-03-04 The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
EP1313872A1 (en) 2000-09-01 2003-05-28 Fujisawa Pharmaceutical Co., Ltd. A method of producing fr901228
WO2002055017A2 (en) 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
AU2002249938B2 (en) 2001-01-10 2006-12-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
WO2002090534A1 (en) 2001-05-02 2002-11-14 The Regents Of The University Of California Method for treating neurodegenerative, psychiatric and other disorders with deacetylase inhibitors
KR20040108528A (ko) 2001-05-30 2004-12-24 더 리젠츠 오브 더 유니버시티 오브 미시간 Bcl2 군 단백질의 소분자 길항제
US7171311B2 (en) 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
ATE526029T1 (de) 2001-08-21 2011-10-15 Astellas Pharma Inc Medizinische verwendung eines histon-deacetylase- hemmers und verfahren zur beurteilung seiner antitumoralen wirkung
US20040259772A1 (en) 2001-08-24 2004-12-23 Antonio Fojo Use of a histone deacetylase inhibitor to increase the entry of an adenoviral agent into a cell
EP1293205A1 (en) 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
US20050123896A1 (en) 2001-10-25 2005-06-09 Benz Christopher C. Screening system for modulators of her2 mediated transcription and her2 modulators identified thereby
WO2003038060A2 (en) 2001-11-01 2003-05-08 The Regents Of The University Of Michigan Small molecule inhibitors targeted at bcl-2
AU2002351898A1 (en) 2001-12-21 2003-07-09 Universite Libre De Bruxelles Method for obtaining the elimination of integrated and functional viruses from infected mammal cells
US20030134423A1 (en) 2002-01-04 2003-07-17 Chu Yong Liang Compounds for delivering substances into cells
EP1482962A4 (en) 2002-02-15 2009-12-23 Sloan Kettering Inst Cancer METHOD OF TREATING THIOREDOXIN-MEDIATED DISEASES (TRX)
JP4274946B2 (ja) 2002-02-20 2009-06-10 国立大学法人九州工業大学 ヒストン脱アセチル化酵素阻害剤およびその製造方法
US20040132825A1 (en) 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
EP2322160A1 (en) 2002-03-04 2011-05-18 Merck HDAC Research, LLC Methods of inducing terminal differentiation
US20040077591A1 (en) 2002-03-28 2004-04-22 The Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease
WO2003084611A1 (en) 2002-04-05 2003-10-16 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide for therapy of kidney cancer
MXPA04010199A (es) 2002-04-15 2005-07-05 Sloan Kettering Inst Cancer Terapia en combinacion para el tratamiento de cancer.
US6809118B2 (en) 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
US20040002447A1 (en) 2002-06-04 2004-01-01 Regents Of The University Of California Induction of insulin expression
US20050065596A1 (en) 2002-07-24 2005-03-24 Xufan Tseng Stents capable of controllably releasing histone deacetylase inhibitors
WO2004017996A1 (ja) 2002-08-20 2004-03-04 Yamanouchi Pharmaceutical Co., Ltd. 関節軟骨細胞外マトリクス分解阻害剤
AU2003259521A1 (en) 2002-09-13 2004-04-30 Mcguire Va Medical Center 111K Combination of a) n-{5-(4-(4-methyl-piperazino-methyl)-benzoylamido)-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia
SE0300098D0 (sv) 2003-01-15 2003-01-15 Forskarpatent I Syd Ab Use of cyclin D1 inhibitors
WO2004064727A2 (en) 2003-01-16 2004-08-05 Georgetown University Method of cancer treatment using hdac inhibitors
WO2004074478A1 (ja) 2003-02-19 2004-09-02 Astellas Pharma Inc. ヒストンデアセチラーゼ阻害剤の抗腫瘍効果の予測方法
US7988957B2 (en) 2003-04-25 2011-08-02 Genesis Healthcare Corp. Gene introduction efficiency enhancer
US20040213826A1 (en) 2003-04-28 2004-10-28 Marx Steven O. Medical devices and methods for inhibiting proliferation of smooth muscle cells
EP1491188A1 (en) 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
EP1638541B1 (en) 2003-06-27 2010-05-19 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
HRP20060073B1 (hr) 2003-07-23 2014-03-14 Bayer Healthcare Llc Fluoro supstituirana omega-karboksiaril difenil urea za lijeäśenje i prevenciju bolesti i stanja
US20080221080A1 (en) * 2003-08-25 2008-09-11 James Douglas Griffin Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias
PT1663194E (pt) 2003-08-26 2010-07-06 Merck Hdac Res Llc Utilizaã†o de saha para o tratamento de mesotelioma
CN1964714B (zh) 2003-08-29 2011-09-28 Hdac默克研究有限责任公司 辛二酰苯胺异羟肟酸和吉西他滨在制备用于治疗癌症的药物中的用途
US20050059682A1 (en) 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
AU2004273910A1 (en) 2003-09-18 2005-03-31 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
MXPA06003222A (es) 2003-09-25 2006-05-22 Astellas Pharma Inc Agente antitumoral que comprende un inhibidor de histona desacetilasa y un inhibidor de topoisomerasa ii.
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US20060270016A1 (en) 2003-11-14 2006-11-30 Holm Per S Novel adenoviruses, nucleic acids that code for the same and the use of said viruses
WO2005051430A1 (de) 2003-11-14 2005-06-09 Per Sonne Holm Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
WO2005053609A2 (en) 2003-11-26 2005-06-16 Guilford Pharmaceuticals Inc. Methods of nad+-dependent deacetylase inhibitors
EP1713460A2 (en) 2003-12-10 2006-10-25 Wisconsin Alumni Research Foundation Fk228 analogs and their use as hdac-inhibitors
US20050187148A1 (en) 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
EP1725873B1 (en) 2004-02-27 2009-07-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pharmacodynamic assays using flow cytometry.
GB0405349D0 (en) 2004-03-10 2004-04-21 Univ Birmingham Cancer therapy and medicaments therefor
ITMI20040876A1 (it) 2004-04-30 2004-07-30 Univ Degli Studi Milano Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari
EP1591109B1 (en) 2004-04-30 2008-07-02 TopoTarget Germany AG Formulation comprising histone deacetylase inhibitor exhibiting biphasic release
US20050261174A1 (en) 2004-05-20 2005-11-24 Paul Lewer Insecticidal activity of a cyclic peptide
WO2005117930A2 (en) 2004-06-04 2005-12-15 Sloan-Kettering Institute For Cancer Research Use of thioredoxin measurements for diagnostics and treatments
US7470722B2 (en) 2004-06-10 2008-12-30 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
US20060018921A1 (en) 2004-07-16 2006-01-26 Baylor College Of Medicine Histone deacetylase inhibitors and cognitive applications
ATE517901T1 (de) 2004-09-06 2011-08-15 Bayer Schering Pharma Ag Pyrazolopyrimidine als hemmer der proteinkinase b (akt)
CA2586228A1 (en) * 2004-11-17 2006-05-26 The University Of Chicago Histone deacetylase inhibitors and methods of use
WO2006060382A2 (en) 2004-11-30 2006-06-08 Trustees Of The University Of Pennsylvania Use of hdac and/or dnmt inhibitors for treatment of ischemic injury
WO2006060429A2 (en) 2004-12-03 2006-06-08 Novartis Ag Identification of variants in histone deacetylase 1 (hdac1) to predict drug response
US20060128660A1 (en) 2004-12-10 2006-06-15 Wisconsin Alumni Research Foundation FK228 analogs and methods of making and using the same
GB0511266D0 (en) 2005-06-02 2005-07-13 Trust Chemical compounds
EP1743654A1 (en) 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
WO2007040522A1 (en) 2005-09-30 2007-04-12 The Ohio State Research Foundation Antitumor agents
EP1957673A2 (en) 2005-11-10 2008-08-20 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Materials and methods for abcb1 polymorphic variant screening, diagnosis, and treatment
US20070129290A1 (en) 2005-11-18 2007-06-07 Or Yat S Metabolite derivatives of the HDAC inhibitor FK228
EP2049139A4 (en) 2006-04-24 2009-06-24 Gloucester Pharmaceuticals Inc TREATMENT OF TUMORS EXPRESSING RAS
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
EP2040731A4 (en) 2006-06-09 2010-05-19 Merrion Res Iii Ltd SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR
US7857804B2 (en) 2006-09-01 2010-12-28 Mccaffrey Timothy A Use of Bcl inhibitors for the prevention of fibroproliferative reclosure of dilated blood vessels and other iatrogenic fibroproliferative disorders
EP2102230A2 (en) 2006-12-29 2009-09-23 Gloucester Pharmaceuticals, Inc. Purifiction of romidepsin
BRPI0720734A2 (pt) * 2006-12-29 2014-01-07 Gloucester Pharmaceuticals Inc Preparação da romidepsina
WO2009064300A1 (en) * 2007-11-15 2009-05-22 The Johns Hopkins University Combinations of hdac inhibitors and cytokines/growth factors
MX2011001132A (es) * 2008-07-30 2011-08-17 Gloucester Pharmaceuticals Inc Tratamiento acelerado.

Similar Documents

Publication Publication Date Title
JP2013540734A5 (enExample)
JP2009539769A5 (enExample)
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
MX2010010026A (es) Agente para tratar enfermedad.
JP2012180381A5 (enExample)
JP2016539156A5 (enExample)
BRPI0607168A2 (pt) terapia de combinação parenteral, composição farmacêutica, processo para preparar uma composição farmacêutica e método de tratamento
JP2010507567A5 (enExample)
JP2015212268A5 (enExample)
JP2008519047A5 (enExample)
JP2006504795A5 (enExample)
JP2012193216A5 (enExample)
JP2013541583A5 (enExample)
US20150231198A1 (en) Combination therapy for hematological malignancies
RU2017134443A (ru) Способ лечения с применением традипитанта
NZ595767A (en) Composition for the treatment of prostate cancer
RU2013123646A (ru) Комбинированная композиция
JP2015522033A5 (enExample)
JP2019511496A5 (enExample)
JP2019526559A5 (enExample)
RU2015115398A (ru) N-ацетил-L-цистеин для применения в экстракорпоральном оплодотворении
PE20130782A1 (es) Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo
JP2019535830A5 (enExample)
JP2010523660A5 (enExample)
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol